We don’t run corporate ads. We don’t shake our readers down for money every month or every quarter like some other sites out there. We provide our site for free to all, but the bandwidth we pay to do so doesn’t come cheap. A generous donor is matching all donations of $100 or more! So please donate now to double your punch!
Partisan bitterness has become a familiar feature of Capitol Hill politics. But given the recent debt debacle, it was little surprise that two committee rooms full of congressional lawmakers were giddy at the chance to sing bipartisan praises and wave through legislation that criminalizes possession and sale of “K2,” “spice,” “bath salts,” and other synthetic drugs.
Despite growing consensus that there is an urgent need for a new direction in our nation’s drug policies, and recognition from the Global Commission on Drug Policy and others that the 40 year old war on drugs is a resounding failure, many lawmakers are still shy to question the wisdom of proposals to criminalize more people and the drugs they use.
Synthetic drugs that imitate the effects of marijuana and other illegal drugs have been sensationalized since they first appeared on store shelves. Many people are attracted to these products because the drugs do not show up in drug tests and it was not a crime to use or sell them until recently.
Much controversy has centered on the marketing of these drugs as incense or other household products even though they are often consumed. Rather than step in to regulate synthetic drugs, impose age restrictions and product labeling requirements, the government did nothing until several tragic events involving young people received extensive media coverage.
State and federal lawmakers have forged ahead with proposals to ban synthetic drugs before scientists could better understand and evaluate the products for health risks and benefits. Empirical evidence has yet to surface that shows synthetic drugs pose a threat to public health that warrants criminalization.
Lawmakers have a long track record of passing ineffective laws, and its unwavering support for the war on drugs is no exception. Enforcement of marijuana prohibition, in particular, has wasted billions of dollars subjecting millions of American citizens to arrest for nonviolent drug law violations. Marijuana law violations make up half of all drug arrests annually.
And just as we have seen with marijuana, criminalizing synthetic drugs will cede control of the drugs to the criminal market. Our policy should enable the government to enforce strict regulations and controls on a legal market for synthetic drugs that monitors production, minimizes public harm and generates tax revenue.
Congress continues to vigorously fund and escalate the drug war even as Washington seeks to reduce federal spending. Enforcing a federal ban on synthetic drugs won’t be cheap. Moreover, organizations such as the Heritage Foundation have cautioned against creating unnecessary federal crimes that inappropriately expand the reach of the federal government into local affairs. Since the vast majority of drug enforcement is carried out by state and local agencies, Congress is essentially passing the costs of this legislation on to them.
Commenting on synthetic drugs during a committee session this week, Sen. Dianne Feinstein (D-CA) remarked that “we are in a new era of drugs.”
A new era calls for a new approach, and Congress has an opportunity here to provide for comprehensive drug education, rigorous scientific study to better understand what is in synthetic drugs, and a robust system of regulation and control of the synthetic drug market. Lawmakers need not look far for a successful model. The federal government’s approach to dealing with tobacco has been enormously successful at reducing youth and adult tobacco use in recent decades and millions of people didn’t have to be arrested and branded with criminal convictions to achieve success.
Lawmakers must put the brakes on this failed approach to drug policy, stop wasting taxpayer dollars and destroying people’s lives.
Grant Smith is the federal policy coordinator in the Drug Policy Alliance’s office of national affairs in Washington, D.C.